Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 55% Improvement Relative Risk ICU admission 66% Mortality (b) 28% ICU admission (b) 26% Ivermectin for COVID-19  Mayer et al.  EARLY TREATMENT Is early treatment with ivermectin beneficial for COVID-19? Retrospective 21,232 patients in Argentina Lower mortality (p<0.0001) and ICU admission (p<0.0001) c19ivm.org Mayer et al., Frontiers in Public Health, Sep 2021 Favors ivermectin Favors control

Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients

Mayer et al., Frontiers in Public Health, doi:10.3389/fpubh.2022.813378 (date from preprint)
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19ivm.org
Retrospective 21,232 patients in Argentina, 3,266 assigned to ivermectin treatment, showing lower mortality with treatment. Greater benefits were seen for patients >40, and a dose dependent response was found. For more discussion see twitter.com.
This is the 63rd of 103 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
50 studies are RCTs, which show efficacy with p=0.00000014.
risk of death, 55.1% lower, RR 0.45, p < 0.001, treatment 3,266, control 17,966, adjusted per study, odds ratio converted to relative risk, Figure 3, multivariable.
risk of ICU admission, 65.9% lower, RR 0.34, p < 0.001, treatment 3,266, control 17,966, adjusted per study, odds ratio converted to relative risk, Figure 3, multivariable.
risk of death, 27.6% lower, RR 0.72, p = 0.03, treatment 3,266, control 17,966, odds ratio converted to relative risk, unadjusted.
risk of ICU admission, 26.0% lower, RR 0.74, p = 0.13, treatment 3,266, control 17,966, odds ratio converted to relative risk, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mayer et al., 23 Sep 2021, retrospective, Argentina, peer-reviewed, 14 authors, dosage 540μg/kg days 1-5, mean prescribed dose.
This PaperIvermectinAll
Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients
Marcos Alejandro Mayer, Alejandro Krolewiecki, Alejandro Ferrero, Marcelo Bocchio, Juan Barbero, Marcos Miguel, Ariel Paladini, Carlos Delgado, Juan Ramón Ojeda, Claudia Elorza, Ana Bertone, Pedro Emanuel Fleitas, Gustavo Vera, Mario Rubén Kohan
Frontiers in Public Health, doi:10.3389/fpubh.2022.813378
Background: In the absence of antiviral alternatives, interventions under research for COVID-19 might be offered following guidelines from WHO for monitored emergency use of unregistered and experimental interventions (MEURI). Ivermectin is among several drugs explored for its role against SARS-CoV-2, with a well-known safety profile but conflicting data regarding clinical utility for COVID-19. The aim of this report is to inform on the results of a MEURI Program of high-dose ivermectin in COVID-19 carried out by the Ministry of Health of the Province of La Pampa, Argentina. Methods: COVID-19 subjects, within 5 days of symptoms onset were invited to participate in the program, which consisted in the administration of ivermectin 0.6 mg/kg/day for 5 days plus standard of care. Active pharmacosurveillance was performed for 21 days, and hepatic laboratory assessments were performed in a subset of patients. Frequency of Intensive Care Unit (ICU) admission and COVID-19-related mortality of subjects in the ivermectin intention to treat group were compared with that observed in inhabitants of the same province during the same period not participating in the program. Results: From 21,232 subjects with COVID-19, 3,266 were offered and agreed to participate in the ivermectin program and 17,966 did not and were considered as controls. A total of 567 participants reported 819 adverse events (AEs); 3.13% discontinued ivermectin due to adverse events. ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2 vs. 2.0%, odds ratio 0.608; p = 0.024). Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5 vs. 2.1%, odds ratio 0.720; p = 0.029), as well as in subjects ≥ 40 year-old (2.7 vs. 4.1%, odds ratio 0.655; p = 0.005). Conclusions: This report highlights the safety and possible efficacy of high dose ivermectin as a potentially useful intervention deserving public health-based consideration for COVID-19 patients.
ETHICS STATEMENT The studies involving human participants were reviewed and approved by the Provincial Ethics Committee of La Pampa, and participating individuals provided written informed consent. The patients/participants provided their written informed consent to participate in this study. AUTHOR CONTRIBUTIONS ACKNOWLEDGMENTS The authors would like to acknowledge the authorities of the Government of the Province of La Pampa, Argentina, for their support, and to the Ivermectin Monitored Intervention program collaborators: María Alejandra Ramallo; Andrea Barbero; Liliana Torres; Nadia Paola Andresco Soto; Lucía Martín; Analisa Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Copyright © 2022 Mayer, Krolewiecki, Ferrero, Bocchio, Barbero, Miguel, Paladini, Delgado, Ojeda, Elorza, Bertone, Fleitas, Vera and Kohan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in..
References
Abdala, None
Alfonso, Gastón, Jouly, None
Andrea, None
Arroyo, None
Astesano, Baez, Ulivetti, None
Barboza, None
Barra, None
Barrionuevo, None
Barrionuevo, None
Bessone, Hernandez, Tagle, Arrese, Parana et al., Drug-induced liver injury: a management position paper from the Latin American Association for Study of the liver, Ann Hepatol, doi:10.1016/j.aohep.2021.100321
Biber, Mandelboim, Harmelin, Ram, Shaham, Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 -A double-blind, randomized placebo-controlled trial, medRxiv, doi:10.1101/2021.05.31.21258081
Bissio, Allara, Guerrero, None
Bramante, None
Bryant, Lawrie, Dowswell, Fordham, Mitchell et al., Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines, Am J Ther, doi:10.1097/MJT.0000000000001442
Burgahrtd, Puglie, None
Calo, None
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res, doi:10.1016/j.antiviral.2020.104787
Cappozi, Vanesa, None
Carasay, None
Ceferino, None
Cervellini, Soto, Soto, None
Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with nonsevere COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
De Los Santos, None
De, Prida, None
Delfino, None
Díaz, Macayo, None
Edwards, Dingsdale, Helsby, Orme, Breckenridge, The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution, Eur J Clin Pharmacol, doi:10.1007/BF00637608
Elias, Fernando, None
Ester, Carla, Morales, Marsollier, Mariné del Valle Plizzo
Fischman, None
Fritz, Morris, Richler, Effect size estimates: current use, calculations, and interpretation, J Exp Psychol Gen, doi:10.1037/a0024338
Furik, Baizero, None
Galarza, None
Garro, Santiago, None
Gimenez, None
González, Hermua, None
Guerbilli, None
Gutierrez, None
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Hernandez, None
Hill, Garratt, Levi, Falconer, Ellis et al., Expression of concern: "meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection, Open Forum Infect Dis, doi:10.1093/ofid/ofab394
Jerving, The long road ahead for COVID-19 vaccination in Africa, Lancet, doi:10.1016/S0140-6736(21)01967-X
Jorja, Daniel, None
Julia, None
Kow, Hasan, Pitfalls in reporting sample size calculation across randomized controlled trials involving ivermectin for the treatment of COVID-19, Am J Ther, doi:10.1097/MJT.0000000000001441
Kredes, None
Krolewiecki, Lifschitz, Moragas, Travacio, Valentini et al., Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial, EClinicalMedicine, doi:10.1016/j.eclinm.2021.100959
Laing, Devaney, Ivermectin -old drug, new tricks?, Trends Parasitol, doi:10.1016/j.pt.2017.02.004
Leguizamon, García, None
León, None
Lluch, None
Londero, None
Luft, None
López, None
López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, J Am Med Assoc, doi:10.1001/jama.2021.3071
Maison, None
Manary, It's the context!, Am J Clin Nutr, doi:10.3945/ajcn.115.108399
María, Martin, Tabares, Godoy, Minudri, None
Mas, Carrizo, None
Matamoros, Sanchez, Gabrie, Juarez, Ceballos et al., Efficacy and safety of albendazole and high-dose ivermectin coadministration in schoolaged children infected with Trichuris trichiura in Honduras: a randomized controlled trial, Clin Infect Dis, doi:10.1093/cid/ciab365
Mendoza, None
Mercado, Ortiz, None
Moline, Whitaker, Deng, Rhodes, Milucky et al., Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 years -COVID-NET, 13 states, Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7032e3
Monarde, Rojas, Balsa, None
Morales, None
Moran, Abdala, None
Natividad, None
Navarro, Camprubí, Requena-Méndez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: a systematic review and metaanalysis, J Antimicrob Chemother, doi:10.1093/jac/dkz524
Neil, Fenton, Kow, Hasan, Popp et al., Bayesian hypothesis testing and hierarchical modeling of ivermectin effectiveness, Am J Ther, doi:10.1097/MJT.0000000000001450
Omura, Crump, Ivermectin: panacea for resource-poor communities?, Trends Parasitol, doi:10.1016/j.pt.2014.07.005
Padhi, Pati, Panda, Effect of ivermectin in the treatment of COVID-19: a trial sequential analysis highlighted the requirement of additional randomized controlled trials, Clin Infect Dis, doi:10.1093/cid/ciab692
Puglie, María, None
Pérez, Bustos, None
Quiroga, None
Quiroga, Silvia Romera, None
Ramos, None
Redel, Baigorria, None
Renzo, Raúl, Gavotti, Del, Godino, None
Roman, Burela, Pasupuleti, Piscoya, Vidal et al., Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials, Clin Infect Dis, doi:10.1101/2021.05.21.21257595
Saini, Vago, None
Sajid, Iqbal, Muhammad, Iqbal, Immunomodulatory effect of various anti-parasitics: a review, Parasitology, doi:10.1017/S0031182005009108
Schneider, None
Segatori, Garona, Caligiuri, Bizzotto, Lavignolle et al., Effect of ivermectin and atorvastatin on nuclear localization of importin alpha and drug target expression profiling in host cells from nasopharyngeal swabs of SARS-CoV-2-positive patients, Viruses, doi:10.3390/v13102084
Sepulveda, None
Siemieniuk, Bartoszko, Ge, Zeraatkar, Izcovich et al., Drug treatments for covid-19: living systematic review and network meta-Analysis, BMJ, doi:10.1136/bmj.m2980
Smit, Ochomo, Aljayyoussi, Kwambai, Abong et al., Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial, Lancet Infect Dis, doi:10.1016/S1473-3099(18)30163-4
Soledad, None
Solett, Rocío, None
Sosa, Bibiana Widemman, None
Sosa, Cepeda, None
Sosa, Schan, None
Stern, None
Suputtamongkol, Avirutnan, Mairiang, Angkasekwinai, Niwattayakul et al., Ivermectin accelerates circulating nonstructural protein 1 (NS1) clearance in adult dengue patients: a combined phase 2/3 randomized double-blinded placebo controlled trial, Clin Infect Dis an Off Publ Infect Dis Soc Am, doi:10.1093/cid/ciaa1332
Thompson, Stenehjem, Grannis, Ball, Naleway et al., Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings, N Engl J Med, doi:10.1056/NEJMoa2110362
Thylefors, Alleman, Twum-Danso, Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis, Trop Med Int Heal, doi:10.1111/j.1365-3156.2008.02049.x
Tleyjeh, Kashour, Mandrekar, Petitti, Overlooked shortcomings of observational studies of interventions in coronavirus disease 2019: an illustrated review for the clinician, Open Forum Infect Dis, doi:10.1093/ofid/ofab317
Topfanini, Rovera, None
Torres, Anechi, None
Torres, Matías Altamira; María, Juri, Rosa, None
Torres, Muria, Gómez, None
Vallejos, Zoni, Bangher, Villamandos, Bobadilla et al., Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial, BMC Infect Dis, doi:10.1186/s12879-021-06348-5
Vanderberg, Dayana Iglesias; Maylen, Aimetta, None
Verdugo, None
Villagra, Barbero, Betina, None
Wu, Zhao, Yu, Chen, Song, A new coronavirus associated with human respiratory disease in China, Nature, doi:10.1038/s41586-020-2008-3
Yoshida, Penego, None
{ 'DOI': '10.3389/fpubh.2022.813378', 'ISSN': ['2296-2565'], 'URL': 'http://dx.doi.org/10.3389/fpubh.2022.813378', 'abstract': '<jats:sec><jats:title>Background</jats:title><jats:p>In the absence of antiviral ' 'alternatives, interventions under research for COVID-19 might be offered following guidelines ' 'from WHO for monitored emergency use of unregistered and experimental interventions (MEURI). ' 'Ivermectin is among several drugs explored for its role against SARS-CoV-2, with a well-known ' 'safety profile but conflicting data regarding clinical utility for COVID-19. The aim of this ' 'report is to inform on the results of a MEURI Program of high-dose ivermectin in COVID-19 ' 'carried out by the Ministry of Health of the Province of La Pampa, ' 'Argentina.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>COVID-19 ' 'subjects, within 5 days of symptoms onset were invited to participate in the program, which ' 'consisted in the administration of ivermectin 0.6 mg/kg/day for 5 days plus standard of care. ' 'Active pharmacosurveillance was performed for 21 days, and hepatic laboratory assessments ' 'were performed in a subset of patients. Frequency of Intensive Care Unit (ICU) admission and ' 'COVID-19-related mortality of subjects in the ivermectin intention to treat group were ' 'compared with that observed in inhabitants of the same province during the same period not ' 'participating in the ' 'program.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>From 21,232 ' 'subjects with COVID-19, 3,266 were offered and agreed to participate in the ivermectin ' 'program and 17,966 did not and were considered as controls. A total of 567 participants ' 'reported 819 adverse events (AEs); 3.13% discontinued ivermectin due to adverse events. ICU ' 'admission was significantly lower in the ivermectin group compared to controls among ' 'participants ≥40 year-old (1.2 vs. 2.0%, odds ratio 0.608; <jats:italic>p</jats:italic> = ' '0.024). Similarly, mortality was lower in the ivermectin group in the full group analysis ' '(1.5 vs. 2.1%, odds ratio 0.720; <jats:italic>p</jats:italic> = 0.029), as well as in ' 'subjects ≥ 40 year- old (2.7 vs. 4.1%, odds ratio 0.655; <jats:italic>p</jats:italic> = ' '0.005).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This report ' 'highlights the safety and possible efficacy of high dose ivermectin as a potentially useful ' 'intervention deserving public health-based consideration for COVID-19 ' 'patients.</jats:p></jats:sec>', 'alternative-id': ['10.3389/fpubh.2022.813378'], 'author': [ {'affiliation': [], 'family': 'Mayer', 'given': 'Marcos Alejandro', 'sequence': 'first'}, {'affiliation': [], 'family': 'Krolewiecki', 'given': 'Alejandro', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ferrero', 'given': 'Alejandro', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bocchio', 'given': 'Marcelo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Barbero', 'given': 'Juan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Miguel', 'given': 'Marcos', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Paladini', 'given': 'Ariel', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Delgado', 'given': 'Carlos', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ojeda', 'given': 'Juan Ramón', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Elorza', 'given': 'Claudia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bertone', 'given': 'Ana', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fleitas', 'given': 'Pedro Emanuel', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Vera', 'given': 'Gustavo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Kohan', 'given': 'Mario Rubén', 'sequence': 'additional'}], 'container-title': ['Frontiers in Public Health'], 'content-domain': {'crossmark-restriction': True, 'domain': ['frontiersin.org']}, 'created': {'date-parts': [[2022, 2, 22]], 'date-time': '2022-02-22T05:37:46Z', 'timestamp': 1645508266000}, 'deposited': { 'date-parts': [[2022, 2, 22]], 'date-time': '2022-02-22T05:37:50Z', 'timestamp': 1645508270000}, 'indexed': {'date-parts': [[2022, 2, 22]], 'date-time': '2022-02-22T06:11:54Z', 'timestamp': 1645510314479}, 'is-referenced-by-count': 0, 'issn-type': [{'type': 'electronic', 'value': '2296-2565'}], 'issued': {'date-parts': [[2022, 2, 22]]}, 'license': [ { 'URL': 'https://creativecommons.org/licenses/by/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 2, 22]], 'date-time': '2022-02-22T00:00:00Z', 'timestamp': 1645488000000}}], 'link': [ { 'URL': 'https://www.frontiersin.org/articles/10.3389/fpubh.2022.813378/full', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '1965', 'original-title': [], 'prefix': '10.3389', 'published': {'date-parts': [[2022, 2, 22]]}, 'published-online': {'date-parts': [[2022, 2, 22]]}, 'publisher': 'Frontiers Media SA', 'reference': [ { 'DOI': '10.1038/s41586-020-2008-3', 'article-title': 'A new coronavirus associated with human respiratory disease in China', 'author': 'Wu', 'doi-asserted-by': 'publisher', 'first-page': '265', 'journal-title': 'Nature.', 'key': 'B1', 'volume': '579', 'year': '2020'}, {'key': 'B2', 'unstructured': 'COVID-19 Dashboard.'}, { 'DOI': '10.15585/mmwr.mm7032e3', 'article-title': 'Effectiveness of COVID-19 vaccines in preventing hospitalization among ' 'adults aged ≥65 years - COVID-NET, 13 states, February-April (2021)', 'author': 'Moline', 'doi-asserted-by': 'publisher', 'first-page': '1088', 'journal-title': 'Morb Mortal Wkly Rep.', 'key': 'B3', 'volume': '70', 'year': '2021'}, { 'DOI': '10.1056/NEJMoa2110362', 'article-title': 'Effectiveness of Covid-19 vaccines in ambulatory and inpatient care ' 'settings', 'author': 'Thompson', 'doi-asserted-by': 'publisher', 'first-page': '1355', 'journal-title': 'N Engl J Med.', 'key': 'B4', 'volume': '7', 'year': '2021'}, { 'DOI': '10.1016/S0140-6736(21)01967-X', 'article-title': 'The long road ahead for COVID-19 vaccination in Africa', 'author': 'Jerving', 'doi-asserted-by': 'publisher', 'first-page': '827', 'journal-title': 'Lancet', 'key': 'B5', 'volume': '398', 'year': '2021'}, {'key': 'B6', 'unstructured': '2021'}, { 'DOI': '10.1136/bmj.m2980', 'article-title': 'Drug treatments for covid-19: living systematic review and network ' 'meta-Analysis', 'author': 'Siemieniuk', 'doi-asserted-by': 'publisher', 'first-page': 'm2980', 'journal-title': 'BMJ', 'key': 'B7', 'volume': '370', 'year': '2020'}, { 'key': 'B8', 'unstructured': 'Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National ' 'Institutes of Health.'}, { 'DOI': '10.1016/j.pt.2014.07.005', 'article-title': 'Ivermectin: panacea for resource-poor communities?', 'author': 'Omura', 'doi-asserted-by': 'publisher', 'first-page': '445', 'journal-title': 'Trends Parasitol.', 'key': 'B9', 'volume': '30', 'year': '2014'}, { 'DOI': '10.1111/j.1365-3156.2008.02049.x', 'article-title': 'Operational lessons from 20 years of the Mectizan Donation Program for ' 'the control of onchocerciasis', 'author': 'Thylefors', 'doi-asserted-by': 'publisher', 'first-page': '689', 'journal-title': 'Trop Med Int Heal.', 'key': 'B10', 'volume': '13', 'year': '2008'}, { 'DOI': '10.1016/j.pt.2017.02.004', 'article-title': 'Ivermectin – old drug, new tricks?', 'author': 'Laing', 'doi-asserted-by': 'publisher', 'first-page': '463', 'journal-title': 'Trends Parasitol.', 'key': 'B11', 'volume': '33', 'year': '2017'}, { 'DOI': '10.1093/cid/ciaa1332', 'article-title': 'Ivermectin accelerates circulating nonstructural protein 1 (NS1) ' 'clearance in adult dengue patients: a combined phase 2/3 randomized ' 'double-blinded placebo controlled trial', 'author': 'Suputtamongkol', 'doi-asserted-by': 'publisher', 'first-page': 'e586', 'journal-title': 'Clin Infect Dis an Off Publ Infect Dis Soc Am.', 'key': 'B12', 'volume': '72', 'year': '2021'}, { 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'author': 'Caly', 'doi-asserted-by': 'publisher', 'first-page': '104787', 'journal-title': 'Antivir Res.', 'key': 'B13', 'volume': '178', 'year': '2020'}, { 'article-title': 'Effect of ivermectin in the treatment of COVID-19: a trial sequential ' 'analysis highlighted the requirement of additional randomized ' 'controlled trials', 'author': 'Padhi', 'key': 'B14', 'volume-title': 'Clin Infect Dis', 'year': '2021'}, { 'DOI': '10.1001/jama.2021.3071', 'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults ' 'with mild COVID-19: a randomized clinical trial', 'author': 'López-Medina', 'doi-asserted-by': 'publisher', 'first-page': '1426', 'journal-title': 'J Am Med Assoc.', 'key': 'B15', 'volume': '325', 'year': '2021'}, { 'DOI': '10.1186/s12879-021-06348-5', 'article-title': 'Ivermectin to prevent hospitalizations in patients with COVID-19 ' '(IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial', 'author': 'Vallejos', 'doi-asserted-by': 'publisher', 'first-page': '1', 'journal-title': 'BMC Infect Dis.', 'key': 'B16', 'volume': '21', 'year': '2021'}, { 'DOI': '10.1016/j.eclinm.2021.100959', 'article-title': 'Antiviral effect of high-dose ivermectin in adults with COVID-19: a ' 'proof-of-concept randomized trial', 'author': 'Krolewiecki', 'doi-asserted-by': 'publisher', 'first-page': 'e100959', 'journal-title': 'EClinicalMedicine', 'key': 'B17', 'volume': '37', 'year': '2021'}, { 'DOI': '10.1097/MJT.0000000000001442', 'article-title': 'Ivermectin for prevention and treatment of COVID-19 infection: a ' 'systematic review, meta-analysis, and trial sequential analysis to ' 'inform clinical guidelines', 'author': 'Bryant', 'doi-asserted-by': 'publisher', 'first-page': 'e434', 'journal-title': 'Am J Ther.', 'key': 'B18', 'volume': '28', 'year': '2021'}, { 'DOI': '10.1101/2021.05.31.21258081', 'article-title': 'Favorable outcome on viral load and culture viability using Ivermectin ' 'in early treatment of non-hospitalized patients with mild COVID-19 – A ' 'double-blind, randomized placebo-controlled trial', 'author': 'Biber', 'doi-asserted-by': 'crossref', 'key': 'B19', 'volume-title': 'medRxiv', 'year': '2021'}, { 'DOI': '10.1016/j.eclinm.2020.100720', 'article-title': 'The effect of early treatment with ivermectin on viral load, symptoms ' 'and humoral response in patients with non-severe COVID-19: a pilot, ' 'double-blind, placebo-controlled, randomized clinical trial', 'author': 'Chaccour', 'doi-asserted-by': 'publisher', 'first-page': '100720', 'journal-title': 'EClinicalMedicine.', 'key': 'B20', 'volume': '32', 'year': '2021'}, { 'article-title': 'Ethical issues related to study design for trials on therapeutics for ' 'Ebola Virus Disease', 'first-page': '1', 'key': 'B21', 'volume-title': 'WHO Ethics Work Gr Meet', 'year': '2014'}, { 'DOI': '10.1016/j.aohep.2021.100321', 'article-title': 'Drug-induced liver injury: a management position paper from the Latin ' 'American Association for Study of the liver', 'author': 'Bessone', 'doi-asserted-by': 'publisher', 'first-page': '100321', 'journal-title': 'Ann Hepatol.', 'key': 'B22', 'volume': '24', 'year': '2021'}, { 'DOI': '10.1093/jac/dkz524', 'article-title': 'Safety of high-dose ivermectin: a systematic review and meta-analysis', 'author': 'Navarro', 'doi-asserted-by': 'publisher', 'first-page': '827', 'journal-title': 'J Antimicrob Chemother.', 'key': 'B23', 'volume': '75', 'year': '2020'}, { 'DOI': '10.1016/S1473-3099(18)30163-4', 'article-title': 'Safety and mosquitocidal efficacy of high-dose ivermectin when ' 'co-administered with dihydroartemisinin-piperaquine in Kenyan adults ' 'with uncomplicated malaria (IVERMAL): a randomised, double-blind, ' 'placebo-controlled trial', 'author': 'Smit', 'doi-asserted-by': 'publisher', 'first-page': '615', 'journal-title': 'Lancet Infect Dis.', 'key': 'B24', 'volume': '18', 'year': '2018'}, { 'DOI': '10.1093/cid/ciab365', 'article-title': 'Efficacy and safety of albendazole and high-dose ivermectin ' 'co-administration in schoolaged children infected with Trichuris ' 'trichiura in Honduras: a randomized controlled trial', 'author': 'Matamoros', 'doi-asserted-by': 'publisher', 'first-page': '1203', 'journal-title': 'Clin Infect Dis', 'key': 'B25', 'volume': '73', 'year': '2021'}, { 'DOI': '10.1007/BF00637608', 'article-title': 'The relative systemic availability of ivermectin after administration ' 'as capsule, tablet, and oral solution', 'author': 'Edwards', 'doi-asserted-by': 'publisher', 'first-page': '681', 'journal-title': 'Eur J Clin Pharmacol.', 'key': 'B26', 'volume': '35', 'year': '1988'}, { 'DOI': '10.1093/ofid/ofab394', 'article-title': 'Expression of concern: “meta-analysis of randomized trials of ' 'ivermectin to treat SARS-CoV-2 infection', 'author': 'Hill', 'doi-asserted-by': 'publisher', 'first-page': 'ofab394', 'key': 'B27', 'volume': '8', 'year': '2021'}, { 'DOI': '10.1101/2021.05.21.21257595', 'article-title': 'Ivermectin for the treatment of COVID-19: a systematic review and ' 'meta-analysis of randomized controlled trials', 'author': 'Roman', 'doi-asserted-by': 'crossref', 'key': 'B28', 'volume-title': 'Clin Infect Dis.', 'year': '2021'}, { 'DOI': '10.1097/MJT.0000000000001450', 'article-title': 'Bayesian hypothesis testing and hierarchical modeling of ivermectin ' 'effectiveness', 'author': 'Neil', 'doi-asserted-by': 'publisher', 'first-page': 'CD015017', 'journal-title': 'Am J Ther.', 'key': 'B29', 'volume': '28', 'year': '2021'}, { 'DOI': '10.3390/v13102084', 'article-title': 'Effect of ivermectin and atorvastatin on nuclear localization of ' 'importin alpha and drug target expression profiling in host cells from ' 'nasopharyngeal swabs of SARS-CoV-2- positive patients', 'author': 'Segatori', 'doi-asserted-by': 'publisher', 'first-page': '2084', 'journal-title': 'Viruses.', 'key': 'B30', 'volume': '13', 'year': '2021'}, { 'DOI': '10.1038/s41429-020-0336-z', 'article-title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 ' 'complementary regimen', 'author': 'Heidary', 'doi-asserted-by': 'publisher', 'first-page': '593', 'journal-title': 'J Antibiot.', 'key': 'B31', 'volume': '72', 'year': '2020'}, { 'DOI': '10.1017/S0031182005009108', 'article-title': 'Immunomodulatory effect of various anti-parasitics: a review', 'author': 'Sajid', 'doi-asserted-by': 'publisher', 'first-page': '301', 'journal-title': 'Parasitology.', 'key': 'B32', 'volume': '132', 'year': '2006'}, { 'DOI': '10.3945/ajcn.115.108399', 'article-title': "It's the context! Am J Clin Nutr", 'author': 'Manary', 'doi-asserted-by': 'publisher', 'first-page': '693', 'key': 'B33', 'volume': '101', 'year': '2015'}, { 'DOI': '10.1097/MJT.0000000000001441', 'article-title': 'Pitfalls in reporting sample size calculation across randomized ' 'controlled trials involving ivermectin for the treatment of COVID-19', 'author': 'Kow', 'doi-asserted-by': 'publisher', 'first-page': 'e616', 'journal-title': 'Am J Ther.', 'key': 'B34', 'volume': '28', 'year': '2021'}, { 'DOI': '10.1037/a0024338', 'article-title': 'Effect size estimates: current use, calculations, and interpretation', 'author': 'Fritz', 'doi-asserted-by': 'publisher', 'first-page': '2', 'journal-title': 'J Exp Psychol Gen.', 'key': 'B35', 'volume': '141', 'year': '2012'}, { 'DOI': '10.1093/ofid/ofab317', 'article-title': 'Overlooked shortcomings of observational studies of interventions in ' 'coronavirus disease 2019: an illustrated review for the clinician', 'author': 'Tleyjeh', 'doi-asserted-by': 'publisher', 'first-page': '1', 'journal-title': 'Open Forum Infect Dis.', 'key': 'B36', 'volume': '8', 'year': '2021'}], 'reference-count': 36, 'references-count': 36, 'relation': {}, 'score': 1, 'short-container-title': ['Front. Public Health'], 'short-title': [], 'source': 'Crossref', 'subject': ['Public Health, Environmental and Occupational Health'], 'subtitle': [], 'title': [ 'Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 ' 'Patients'], 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.3389/crossmark-policy', 'volume': '10'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit